- Home
- ADSE vs STOK Comparison
ADSE vs STOK Comparison
Compare ADSE & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- STOK
- Stock Information
- Founded
- ADSE 1980
- STOK 2014
- Country
- ADSE Ireland
- STOK United States
- Employees
- ADSE N/A
- STOK N/A
- Industry
- ADSE Industrial Specialties
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- STOK Health Care
- Exchange
- ADSE Nasdaq
- STOK Nasdaq
- Market Cap
- ADSE 713.5M
- STOK 638.8M
- IPO Year
- ADSE N/A
- STOK 2019
- Fundamental
- Price
- ADSE $11.10
- STOK $13.39
- Analyst Decision
- ADSE
- STOK Strong Buy
- Analyst Count
- ADSE 0
- STOK 5
- Target Price
- ADSE N/A
- STOK $27.75
- AVG Volume (30 Days)
- ADSE 85.6K
- STOK 605.2K
- Earning Date
- ADSE 09-11-2025
- STOK 08-06-2025
- Dividend Yield
- ADSE N/A
- STOK N/A
- EPS Growth
- ADSE N/A
- STOK N/A
- EPS
- ADSE N/A
- STOK 0.88
- Revenue
- ADSE $113,896,884.00
- STOK $190,908,000.00
- Revenue This Year
- ADSE $219.58
- STOK $378.84
- Revenue Next Year
- ADSE N/A
- STOK N/A
- P/E Ratio
- ADSE N/A
- STOK $15.11
- Revenue Growth
- ADSE 2.45
- STOK 2333.81
- 52 Week Low
- ADSE $9.00
- STOK $5.35
- 52 Week High
- ADSE $16.35
- STOK $16.15
- Technical
- Relative Strength Index (RSI)
- ADSE 35.47
- STOK 72.60
- Support Level
- ADSE $10.00
- STOK $11.66
- Resistance Level
- ADSE $13.90
- STOK $12.11
- Average True Range (ATR)
- ADSE 0.86
- STOK 0.47
- MACD
- ADSE -0.20
- STOK 0.03
- Stochastic Oscillator
- ADSE 8.46
- STOK 85.78
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.